You Searched For "bristol myers squibb" and got 20 results
Sort By:
2 mins read
Bristol Myers surges 10%, its biggest increase since 2008, after boosting profit forecast
Bristol Myers Squibb raised profit forecasts and beat revenue estimates amid strong sales for its b…
Kelly Cloonan  Â
1 min read
Bristol Myers Squibb to invest â‚ą800 crore to set up drug development, IT facility in Hyderabad
Bristol Myers Squibb, a world's leading biopharmaceutical company will establish a state of-the-art…
PTI Â Â
2 mins read
Rep. Katie Porter ripped into pharma executive Mark Alles for repeated price hikes on the cancer drug Revlimid
"The drug didn't get any better, the cancer patients didn't get any better, you just got better at …
Lauren Frias  Â
2 mins read
'Big Short' investor Michael Burry discloses new bets on Bristol-Myers Squibb and General Dynamics — and reveals he sold CVS Health and Lockheed Martin
Burry's Scion Asset Management swapped out four of its six US stocks last quarter, helping to boost…
Theron Mohamed  Â
1 min read
Bristol-Myers Squibb is buying Celgene in a $74 billion deal
Brendan McDermid/Reuters
Lydia Ramsey  Â
3 mins read
Here's why Bristol-Myers Squibb's record-breaking $74 billion biotech deal is facing investor backlash
"We now have six near-term launch opportunities, and I stress the term 'near-term' - a number of th…
Emma Court  Â
1 min read
MyoKardia soars 59% after Bristol-Myers agrees to acquire it for $13 billion in cash
MyoKardia's mavacamten candidate is expected to be submitted to the FDA for approval in the first q…
Matthew Fox  Â
4 mins read
Bristol-Myers Squibb has $2.2 billion at stake if its deal to acquire Celgene falls apart, and opposition is mounting
Deals can be broken up for a variety of reasons. Under Bristol-Myers' agreement with Celgene, there…
Emma Court  Â
3 mins read
Bristol-Myers Squibb just claimed 'a breakthrough in cancer research' - but there's a catch
In a much-anticipated study, BMS showed how its drugs Opdivo and Yervoy stack up when treating lung…
Lydia Ramsey  Â
2 mins read
Bristol-Myers Squibb and Celgene said their huge merger has about $2.5 billion in synergies. That should make employees nervous.
In a presentation to investors, the company gave several clues about where it's likely to cut costs…
Lydia Ramsey  Â
2 mins read
Pharma giant Bristol-Myers Squibb just made another big bet on cancer immunotherapy
Bristol-Myers has two drugs, Opdivo and Yervoy, that are a part of a new class of cancer treatments…
Lydia Ramsey  Â
2 mins read
Bristol-Myers Squibb is selling off a blockbuster drug to help its $74 billion merger with Celgene get approved - and now both stocks are tumbling
"Bristol-Myers Squibb reaffirms the significant value creation opportunity of the acquisition of Ce…
Daniel Strauss  Â
2 mins read
Amgen will buy a blockbuster psoriasis drug for $13.4 billion - and it's part of a plan to get Celgene's mega-merger with Bristol-Myers Squibb approved
The merger would serve as one of the largest pharma deals in the last decade. Though divestiture sa…
Ben Winck  Â
2 mins read
Why Bristol-Myers Squibb just made a $1.85 billion bet on a cancer drug
NKTR-214, on the other hand, is aimed at activating proteins that signal the body's immune system, …
Lydia Ramsey  Â
3 mins read
Bristol-Myers Squibb is planning to launch 8 drugs in 18 months for everything from cancer to multiple sclerosis. Here's what they are and how the $150 billion pharma giant plans to pull it off.
Featured Digital Health Articles: - Telehealth Industry: Benefits, Services & Examples - Valu…
Lydia Ramsey  Â
3 mins read
Why Bristol-Myers Squibb is making a big bet its approach to treating lung cancer is the right one
The data looked at how combinations of two rival immunotherapy drugs - made by Merck and Bristol-My…
Lydia Ramsey  Â
1 min read
Bristol-Myers' record-breaking $74 billion biotech deal is in jeopardy
"Wellington's conclusion is based upon three tenets: 1) the transaction asks BMY shareholders to ac…
Jonathan Garber  Â
2 mins read
Bristol-Myers Squibb won't be going after a fast approval for its lung cancer drug
But not everybody responds to the PD-1 drugs. Just a quarter to a third of non-small cell lung canc…
Lydia Ramsey,Reuters  Â
4 mins read
$82 billion pharma giant Bristol-Myers Squibb just suffered a major setback in its hunt for a lung cancer treatment, but the drugmaker isn't backing away from its controversial strategy
The drugmaker said it had voluntarily withdrawn its application to sell the drugs after speaking wi…
Emma Court  Â
2 mins read
A tiny boutique landed a big role on the $74 billion Bristol-Myers-Celgene deal
Gordon Dyal was a partner at Goldman Sachs for 16 years, rising to the role of co-chairman of the i…